The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

January 18, 2024

Study Completion Date

January 31, 2027

Conditions
NHLDLBCL
Interventions
DRUG

Atezolizumab

Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation

Trial Locations (32)

Unknown

BE-Antwerpen Edegem-UZA, Antwerp

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Brugge-AZBRUGGE, Bruges

BE-Leuven-UZLEUVEN, Leuven

BE-Roeselare-AZDELTA, Roeselare

NL-Den Bosch-JBZ, 's-Hertogenbosch

NL-Amersfoort-MEANDERMC, Amersfoort

NL-Amsterdam-OLVG, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Apeldoorn-GELREAPELDOORN, Apeldoorn

NL-Breda-AMPHIA, Breda

NL-Delft-RDGG, Delft

NL-Dordrecht-ASZ, Dordrecht

NL-Ede-ZGV, Ede

NL-Eindhoven-CATHARINA, Eindhoven

NL-Eindhoven-MAXIMAMC, Eindhoven

NL-Enschede-MST, Enschede

NL-Groningen-UMCG, Groningen

NL-Hilversum-TERGOOI, Hilversum

NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp

NL-Leeuwarden-MCL, Leeuwarden

NL-Leiden-LUMC, Leiden

NL-Maastricht-MUMC, Maastricht

NL-Nieuwegein-ANTONIUS, Nieuwegein

NL-Nijmegen-CWZ, Nijmegen

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Rotterdam-MAASSTADZIEKENHUIS, Rotterdam

NL-Sittard-Geleen-ZUYDERLAND, Sittard

NL-Den Haag-HAGA, The Hague

NL-Tilburg-ETZ, Tilburg

NL-Utrecht-UMCUTRECHT, Utrecht

NL-Zwolle-ISALA, Zwolle

All Listed Sponsors
lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER

NCT03463057 - The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL | Biotech Hunter | Biotech Hunter